Man Group plc Buys Shares of 990,477 Avantor, Inc. $AVTR

Man Group plc purchased a new stake in shares of Avantor, Inc. (NYSE:AVTR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 990,477 shares of the company’s stock, valued at approximately $9,806,000. Man Group plc owned about 0.15% of Avantor at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AVTR. Royal Bank of Canada lifted its holdings in Avantor by 104.3% during the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock valued at $3,302,000 after purchasing an additional 104,022 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after purchasing an additional 5,075 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of Avantor by 40.2% in the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock worth $542,000 after purchasing an additional 11,543 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Avantor in the second quarter valued at approximately $232,000. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Avantor by 214.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVTR. Barclays raised their price objective on shares of Avantor from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, June 24th. Citigroup boosted their target price on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Evercore set a $10.50 price target on Avantor in a report on Monday, July 6th. Wall Street Zen upgraded Avantor from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Finally, Wolfe Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.00.

Avantor Trading Down 0.1%

Shares of Avantor stock opened at $14.60 on Friday. The company’s 50-day moving average price is $12.12 and its 200-day moving average price is $9.77. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 12-month low of $7.26 and a 12-month high of $15.93. The company has a market cap of $9.87 billion, a price-to-earnings ratio of -17.38, a PEG ratio of 11.03 and a beta of 0.89.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter in the previous year, the company earned $0.24 earnings per share. Avantor’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, equities analysts expect that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.